A core industry consensus highlighted at the conference is the critical value of flow cytometry-based CAR-T cell quantification for clinical efficacy evaluation, consistent with CytoArt’s core focus on precise CAR-T monitoring reagents. Our team exhibited an original research poster focused on novel GPRC5D-targeted anti-idiotype detection antibody for multi-model clinical CAR-T measurement.
The poster drew heavy interest from clinical pathologists and translational clinicians; numerous specialists exchanged contact information and expressed intentions to evaluate our GPRC5D antibody products. Our team also built new academic connections with global flow cytometry experts and clinical researchers during on-site technical discussions.
